May, 2026.- In the 2026 advertising ecosystem, healthcare communication demands unprecedented technical precision and strategic agility. Kelly Ofman, who began her career at AbelsonTaylor Group, returns today in a senior leadership role after leading global launches for medical milestones such as LEQEMBI (Alzheimer’s) and Pfizer’s Comirnaty vaccine during the pandemic. For Ofman, this return represents the culmination of a learning cycle within large networks, now channeling that experience into an independent agency model where flexibility and entrepreneurial spirit allow for bolder solutions. Her approach breaks traditional industry silos, integrating strategies for healthcare professionals (HCP) and direct-to-consumer (DTC) efforts under a single human truth and non-negotiable scientific rigor.
In this exclusive interview with Roastbrief, Kelly Ofman breaks down the lessons of operating in high-pressure environments and under intense public scrutiny, where agility must be coupled with ironclad discipline. Ofman shares her framework for navigating complex regulatory environments: involving medical and legal partners from the idea’s inception to ensure that creativity is not just compliant, but differentiating and brave. Discover how her vision of an “integration mindset” is helping shape the next chapter of pharmaceutical advertising, where transparency, speed, and clarity of purpose are the only tools capable of transforming clinical paradigms and winning the trust of a world watching every move in real-time.
- Returning Home: You began your career in pharmaceutical advertising at AbelsonTaylor Group, and now you’re returning in a senior leadership capacity. What does it mean to come full circle, and how has your perspective on the agency—and the industry—evolved since you were last here?
Coming back to AbelsonTaylor Group in a senior leadership role truly feels like a fullcircle moment. I started my career here, and returning now — after years of navigating marketing initiatives across the product lifecycle; from launch through loss of exclusivity — gives me a completely different perspective on both the agency and the industry.
The growth on both sides has been remarkable. The industry has gone through massive consolidation, and that shift has actually reinforced my belief in the value of an independent agency. ATG has the flexibility, focus, and entrepreneurial energy that large holdingcompany networks often struggle to maintain. We can move faster, tailor solutions more precisely, and build teams around client needs rather than rigid structures.
I’m grateful for the resources and exposure I had at larger agencies — they gave me the chance to learn, experiment, and scale big ideas. Now, I can bring that experience back to AT Group and apply it in a more intentional, strategic way. It’s exciting to return with a broader lens and help shape the next chapter of an agency that played such a foundational role in my career.
- Launching LEQEMBI and Myfembree: You led U.S. and global launch strategy for high-profile brands like Eisai’s LEQEMBI (Alzheimer’s) and Pfizer/Sumitomo’s Myfembree (women’s health). What are the unique challenges of launching specialty and immunology brands compared to broader consumer health products? How does the regulatory environment shape every decision?
In many of my recent launches, I’ve had the opportunity to help define entirely new therapeutic categories, including Alzheimer’s, where we introduced the first diseasemodifying therapy to market. Because these products entered spaces with no established standards of care, we weren’t just launching a brand — we were shaping the clinical paradigm itself.
That meant working closely with every stakeholder across the ecosystem — clinicians, payers, health systems, advocacy groups, and caregivers — to build the appropriate diagnosistotreatment pathways, clarify patient identification criteria, and ensure safe, appropriate use. Establishing these frameworks from the ground up is a unique challenge of firstinclass launches, and it requires scientific rigor, crossfunctional alignment, and a deep understanding of how new evidence reshapes practice.
- Comirnaty During Multiple FDA Indication Expansions: You led integrated HCP and DTC efforts for Pfizer’s Comirnaty during multiple FDA indication expansions—a vaccine that was at the center of a global pandemic. What did that experience teach you about agility, stakeholder alignment, and communicating in real-time under immense public scrutiny?
“Unprecedented” became the defining word of the Comirnaty experience — and for good reason. Everything about that launch was new, from navigating accelerated FDA pathways to operating in an environment where teams were essentially “always on” in a remotefirst world. We were making decisions in real time, often balancing the urgency of being first to market with the responsibility of validating every message through rigorous medical, legal, and regulatory review.
The pace felt like pushing a freight train at full speed. The need for clear, accurate education — for both HCPs and consumers — was enormous, but so was the pressure to ensure alignment across every stakeholder before anything went live. That experience taught me the true meaning of agility: not just moving fast, but moving fast with discipline, crossfunctional coordination, and absolute clarity of purpose. It also reinforced how critical transparent communication is when the entire world is watching and information is evolving by the hour.
- Navigating Complex Regulatory Environments: Your experience spans the full product lifecycle in pharma, “navigating complex regulatory environments.” What’s your framework for ensuring that creative and strategic work remains compliant without becoming generic or risk-averse? Where do you push, and where do you pull back?
For me, navigating complex regulatory environments starts long before creative development — it starts with a good brief. If we’re aligned on the jobs to be done, the core insight, and the strategic intent, then we’re building ideas on a foundation that’s already defensible. That clarity is what allows creative to stay compliant without becoming generic.
I bring medical, legal, and regulatory partners in early so we’re shaping the work together rather than negotiating it at the end. When everyone understands the science, the data, and the purpose behind the idea, the guardrails become clearer and the conversations become more collaborative.
Where I push is on precision and differentiation — making sure the work is bold, meaningful, and rooted in clinical truth. If the science supports it and the insight is strong, there’s usually a compliant path forward.
6. Connecting Insight to Execution Across Audiences: Lynnette Hunter noted your ability to “connect insight to execution across audiences and channels.” In pharma marketing, where HCP and DTC strategies often operate in silos, how do you ensure integrated thinking? What’s your process for aligning medical, regulatory, and commercial stakeholders?
Connecting insight to execution across audiences starts with refusing to treat HCP and DTC as separate worlds. In my experience, integrated thinking only happens when you anchor everything — strategy, creative, and execution — to a shared human truth and a shared business objective, even if the expressions differ by audience. Integration isn’t a workflow — it’s a mindset, and it’s something I’ve built into every launch I’ve led.
